Considering how the last news release had the effect of a fart in a tornado, I doubt it.
Currently my largest bio position is in Array Biopharma (ARRY), which popped from about $3.50 to $6 on Monday for their successful trial in BRAF melanoma - their FDA reviews are scheduled for 2017. Binimetinb/Encorafenib is not the first MEK/RAF inhibitor combo on the market, but seeing how they got 14.9m PFS when the next study couldn't even crack 12, they should be poised to take a large share of that market space. There's a minor catalyst in November when they release expanded data from their trial at a major medical conference.
A more speculative position is Synergy (SGYP), which already has its main drug candidate in a successful P3 for chronic constipation and is reporting results for another P3 in irritable bowel in Q4 (very similar indication, so there's a high chance for success). The first of their FDA dates are slated for January '17. Another speculative position is Kite Pharma (KITE), which reported fantastic interim results (50% complete response) for their breakthrough CAR-T therapy in a P2. However, since they have been given breakthrough designation, they feel that they are able to go to the FDA with their current data. It should be noted that there's some skepticism due 2/3 of complete responses relapsing, but it should also be noted that their patient population were chemorefractory having exhausted all options. Giving a CURE to 15% of those people is a groundbreaking achievement, and I have high expectations for them with the FDA, though the road might be rocky with regulatory politics - in 2017, of course.
Bio's been selling off these past few days. Not sure if it's going to continue further, but some of these entry points are beginning to look very attractive.
